2022, doi: 10.1016/j.jacc.2022.05.041
This unprecedented tri-receptor synergy offers researchers a remarkably powerful, comprehensive tool to deeply study complex metabolic signaling interactions and systemic energy homeostasis
Unlike earlier weight-management medicines, retatrutide is a triple receptor agonist , meaning it simultaneously targets three distinct hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
The first two were on diabetes and knee pain
Treatment is eligible for HSA and FSA accounts, making it accessible across all 50 states
Tirzepatide has gained widespread attention due to its strong clinical results, at the same time, interests have been growing around next-generation therapies like Retatrutide